Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ia/Ib of Anselamimab in AL Amyloidosis
NCT02245867Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Oct 2014
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of anselamimab in amyloid light chain amyloidosis (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Maximum Tolerated Dose at 2 years. Started Oct 2014; status: completed.
02
Drugs
anselamimab
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT02245867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02245867.